4.7 Article

Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Journal

KIDNEY INTERNATIONAL
Volume 98, Issue 2, Pages 294-309

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2020.04.020

Keywords

acute kidney disease; acute kidney injury; fluid management; nephrotoxicity; renal replacement therapy; risk stratification

Funding

  1. KDIGO
  2. Akebia Therapeutics
  3. Angion
  4. AMPharma
  5. AstraZeneca
  6. Astute Medical
  7. Atox Bio
  8. Baxter
  9. bioMerieux
  10. BioPorto
  11. Boehringer Ingelheim
  12. CytoSorbents
  13. Edwards
  14. Fresenius Medical Care
  15. GE Healthcare
  16. Grifols
  17. Kyowa Kirin
  18. Novartis
  19. NxStage
  20. Outset
  21. Potrero

Ask authors/readers for more resources

In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the classification and management of acute kidney injury (AKI). The guideline was derived from evidence available through February 2011. Since then, new evidence has emerged that has important implications for clinical practice in diagnosing and managing AKI. In April of 2019, KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: determine best practices and areas of uncertainty in treating AKI; review key relevant literature published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline research needed to improve AKI management. Here, we present the findings of this conference and describe key areas that future guidelines may address.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available